Topline data were announced from a phase 3 trial evaluating secukinumab in patients with polymyalgia rheumatica.
A recent international clinical trial published in the journal of The Lancet Rheumatology found that sarilumab 200 mg every 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback